Business Wire

ATHORA-HOLDING

Share
Athora Announces Full Year 2020 Results

Athora Holding Ltd. (Athora), an insurance and reinsurance group focused on the European market, delivered a solid performance and saw significant growth in 2020. During the year ending 31 December 2020, assets under administration grew to €83 billion, organic capital generation increased in our Belgian and German business units, and the group was pleased to report a strong inaugural estimated Bermuda Solvency Capital Requirement (BSCR) ratio of 242%.

Performance Highlights

  • Assets under administration of €83 billion (2019: €15 billion) boosted by the transformative acquisition of Athora Netherlands (formerly VIVAT). The group now supports over 2.5 million policyholders
  • Group IFRS profit before tax (from continuing operations) for the year of €700 million (2019: €13 million loss). This was primarily attributable to the consolidation of Athora Netherlands for the nine months post-acquisition in April 2020 and gain on acquisition of €213 million
  • Strong organic capital generation (OCG) in two business units well advanced in their integrations, Belgium and Germany, of €185 million (2019: €54 million) supported by asset optimisation and efficiency initiatives
  • IFRS total equity of €4.3 billion (2019: €0.6 billion) largely attributable to the issuance of €2.8 billion of additional equity share capital and IFRS net income1

Financial Strength Highlights

  • Inaugural group estimated BSCR ratio of 242%, following group supervision by the Bermuda Monetary Authority in 2020
  • Successfully raised €1.8 billion of additional equity capital commitments from new and existing shareholders
  • Completed €589 million Senior Bond tender in April reducing Athora Netherlands’ financial leverage
  • Group financial leverage ratio reduced to 26%

Strategic Progress

  • Effectively navigated the challenges posed by Covid-19 with 98% of employees able to work from home, undisrupted customer service and successful asset re-deployment at attractive returns
  • Acquisition of Athora Netherlands enabled Athora to reach critical mass, with significant growth potential
  • Successfully sold strategically non-core assets in Netherlands and Belgium
  • Growing reinsurance track-record following inaugural external reinsurance transaction in December with a leading Irish life insurer
  • Committed to developing our sustainability approach into an holistic ESG strategy for the group

Commenting on the results, Athora Group Chief Executive Officer, Michele Bareggi said:

"2020 was a year of significant progress and growth for this group, despite pandemic related disruption and challenging financial markets. Our solid performance reflects the merits of our business model, together with the added value that our strategic relationship with Apollo brings. We are particularly pleased to have delivered increased organic capital generation in Germany and Belgium, two business units well advanced in the integration of our business model. This resulted in robust closing capital positions in those entities and supported leading levels of customer returns. Financial stability is at the core of our business model as can be seen through our strong 2020 year-end capital position and group estimated BSCR ratio of 242%.

We have completed the first stage of our group’s strategic journey - achieving a critical mass with further potential to grow through the purchase of the second largest life insurer in the Netherlands – and we continue to be focused on supporting local management teams deliver the business case of each business unit including asset redeployment, very focused and effective operations, and selective growth.

I want to thank our employees for their hard work and determination in continuing to shape Athora into a leading life insurance and reinsurance group in Europe. By focusing on our mission, and despite the challenges brought by 2020, they remain committed to serving our over 2.5 million customers, and ensuring that our operations remain resilient. Thanks to their dedication and resourcefulness, we are already demonstrating the value of our business model having achieved more than expected in three years since becoming an independent group.

I look to 2021 with confidence, secure in the knowledge that we are building the right ecosystem to capitalise on the growth opportunities that are available to our group. Thanks to our strong capital position, strategic relationships and supportive investors who share our long-term vision, we are well positioned to capture these opportunities and continue to deliver more value for stakeholders.

About Athora
Athora is a specialised insurance and reinsurance group fully focused on the European market. We concentrate on the large and attractive traditional life and pensions market, with an ambition to become a leading provider of guaranteed life and pensions products in Europe. We serve the needs of individual and corporate customers who continue to demand products offering safety of returns, and also provide innovative M&A and reinsurance solutions to other insurers seeking to enhance their capital position or enact strategic change. Athora's principal subsidiaries are Athora Netherlands N.V. (Amstelveen, Netherlands), Athora Belgium N.V./S.A. (Brussels), Athora Lebensversicherung AG (Wiesbaden, Germany), Athora Ireland plc (Dublin) and Athora Life Re Ltd. (Bermuda). The Athora group employs 2,300 staff and has 2.6 million policyholders with assets under administration of €83 billion (as at 31 December 2020).

For more information, please visit: www.athora.com
LinkedIn: www.linkedin.com/company/athoragroup

(1) In 2020, Athora called €2.8 billion of equity capital comprising €1.5 billion from its first capital raise and €1.3 billion from its second capital raise.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Boyd Unveils a High-Capacity Coolant Distribution Unit with a 2.3 Megawatt Capacity for AI Liquid Cooling Applications8.7.2025 14:05:00 CEST | Press release

Boyd’s ROL2300 Coolant Distribution Unit Efficiently and Reliably Cools Modern High Power AI Processors in Hyperscaler, Colocation, and Enterprise Data Centers Today, Boyd announces a significant expansion of its liquid cooling product portfolio with a new high-capacity coolant distribution unit (CDU). Boyd’s new ROL2300 is a liquid-to-liquid in row system that enables high performance cooling for modern AI processor applications and is immediately available to purchase in volume. To learn more about the ROL2300, watch the video here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708530818/en/ Boyd's high capacity ROL2300 in row coolant distribution unit (CDU) efficiently and reliably cools modern high power AI processors in hyperscale, colocation, and enterprise data centers with up to a 2.3 megawatt capacity. A single ROL2300 can efficiently cool over 10 NVL72 racks. It is optimized to easily fit in data center server

Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD8.7.2025 14:00:00 CEST | Press release

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announce today that the China National Medical Products Administration (NMPA) has approved Heng Qin® (Perfluorohexyloctane Eye Drops) for the treatment of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708514269/en/ Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. According to the Chinese Expert Consensus on M

Esri Launches New E-Commerce Experience for Demographic Data8.7.2025 14:00:00 CEST | Press release

Organizations Can Purchase Updated, Authoritative Datasets Ranging from Census to Retail Demand To further provide individuals and organizations with the authoritative demographic data they need, Esri, the global leader in geographic information system (GIS) technology, has launched a new e-commerce experience for data in the Esri Store. A one-stop shop for enhanced, reliable information relating to people and geography, Esri’s location data store is designed to make these resources more accessible for users that rely on spatial data. “We are thrilled to launch our new e-commerce experience, making it easier than ever for customers to access the data they need to make better decisions,” said Rob Elkins, Esri director of product management. “Organizations will have access to current-year and five-year estimates for more than 2,000 demographic and socioeconomic characteristics in the US, as well as census and American Community Survey (ACS) information, consumer spending trends, market p

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella8.7.2025 14:00:00 CEST | Press release

Researchers aim to discover dominant subtypes of plasmablasts initiating from the MMR vaccine in order to develop neutralizing antibody candidate therapies The Vanderbilt University Medical Center and Parse Biosciences today announced a strategic collaboration to generate a single cell atlas focused on understanding the diversity of plasmablasts – early immune cell clonotypes critical in the formation of neutralizing antibodies – for measles, mumps and rubella. This effort aims to build the most comprehensive understanding of the formation of neutralizing antibodies to the vaccine and to identify the dominant and effective antibodies to these infectious agents. Dr. James Crowe, Director of Vanderbilt's Center for Antibody Therapeutics, will lead the development of the large-scale immune cell study. “This collaboration enables us to create the largest single cell atlas of neutralizing plasmablasts ever assembled,” states Crowe. “By sequencing and mapping tens of millions of B cell recep

ViaLase Announces Strategic Leadership Transitions to Support Commercial Growth8.7.2025 14:00:00 CEST | Press release

ViaLase, Inc., a medical technology company pioneering noninvasive femtosecond laser treatments for glaucoma, today announced key changes to its executive leadership team as the company prepares for commercial launch and regulatory approvals in both the United States and Europe. Tibor Juhasz, PhD, founder and former Chief Executive Officer, has transitioned to the role of President and Chief Technology Officer, where he will continue to guide the company’s technological innovation roadmap. Shawn O’Neil, most recently Chief Commercial Officer, has been appointed Chief Executive Officer. In turn, Pete England has been promoted to Chief Commercial Officer. “These leadership changes mark an important milestone in ViaLase’s evolution,” said Tom Frinzi, Executive Chairman of the Board. “Tibor has done an extraordinary job building a world-class R&D and clinical organization, laying the foundation for what promises to be a major advancement in glaucoma care. His track record as an entrepreneu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye